WallStreetZenWallStreetZen

NASDAQ: CARM
Carisma Therapeutics Inc Stock Ownership - Who owns Carisma Therapeutics?

Insider buying vs selling

Have Carisma Therapeutics Inc insiders been buying or selling?
No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when CARM insiders and whales buy or sell their stock.

CARM Shareholders

What type of owners hold Carisma Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Modernatx Inc12.18%5,059,338$6.58MInsider
Third Rock Ventures LP11.65%4,841,591$6.29MInsider
Clairmark Investments Ltd8.62%3,582,328$4.66MInsider
Leslie Dan8.62%3,582,328$4.66MInsider
Regina Hodits5.53%2,297,546$2.99MInsider
Chidozie Ugwumba5.33%2,215,877$2.88MInsider
Jafco Super V3 Investment Limited Partnership4.63%1,923,226$2.50MInsider
Flagship Ventures Fund Iv LP4.41%1,833,802$2.38MInsider
Blackrock Inc4.18%1,736,368$2.26MInstitution
Vanguard Group Inc3.80%1,579,961$2.05MInstitution

1 of 3

CARM vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CARM20.48%74.42%
LTRN10.20%65.57%Net SellingNet Selling
OCUP1.12%98.88%Net BuyingNet Buying
MRKR1.31%98.69%
ABIO4.76%95.24%Net BuyingNet Buying

Carisma Therapeutics Stock Ownership FAQ

Who owns Carisma Therapeutics?

Carisma Therapeutics (NASDAQ: CARM) is owned by 20.48% institutional shareholders, 74.42% Carisma Therapeutics insiders, and 5.10% retail investors. Modernatx Inc is the largest individual Carisma Therapeutics shareholder, owning 5.06M shares representing 12.18% of the company. Modernatx Inc's Carisma Therapeutics shares are currently valued at $6.37M.

If you're new to stock investing, here's how to buy Carisma Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.